Engineered heparins as new anticoagulant drugs
Loading...
ORCID
https://orcid.org/0000-0003-2219-5833
Other Contributors
Issue Date
Type
Article
Language
ENG
Degree
Alternative Title
Abstract
Heparin is an anionic polysaccharide that is widely used as a clinical anticoagulant. This glycosaminoglycan is prepared from animal tissues in metric ton quantities. Animal-sourced heparin is also widely used in the preparation of low molecular weight heparins that are gaining in popularity as a result of their improved pharmacological properties. The recent contamination of pharmaceutical heparin together with concerns about increasing demand for this life saving drug and the fragility of the heparin supply chain has led the scientific community to consider other potential sources for heparin. This review examines progress toward the preparation of engineered heparins through chemical synthesis, chemoenzymatic synthesis, and metabolic engineering.
Description
Bioengineering & Translational Medicine, 2, 17–30
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Full Citation
Engineered heparins as new anticoagulant drugs, D. Vaidyanathan, A. Williams, J. S. Dordick, M. A.G. Koffas, Robert J. Linhardt, Bioengineering & Translational Medicine, 2, 17–30, 2016.
Publisher
Wiley